Last reviewed · How we verify
CERITINIB
Ceritinib inhibits ALK, IGF-1R, InsR, and ROS1 kinases, particularly effective against ALK, blocking its autophosphorylation and downstream signaling.
At a glance
| Generic name | CERITINIB |
|---|---|
| Drug class | Kinase Inhibitor [EPC] |
| Target | ALK, IGF-1R, InsR, ROS1 |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2014 |
Mechanism of action
Ceritinib is a kinase inhibitor that primarily targets ALK, preventing it from activating and thus stopping the growth of cancer cells that depend on ALK. It also affects other kinases like IGF-1R and InsR, but its main impact is on ALK, which is crucial for certain types of cancer, such as those with EML4-ALK fusion proteins.
Approved indications
Common side effects
- diarrhea
- nausea
- vomiting
Key clinical trials
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (PHASE2)
- Next Generation Personalized Neuroblastoma Therapy (PHASE1)
- Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma (PHASE2)
- Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma (PHASE1)
- Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PHASE2)
- Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC (PHASE1)
- Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study (PHASE4)
- Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CERITINIB CI brief — competitive landscape report
- CERITINIB updates RSS · CI watch RSS